GT Biopharma, Inc.
GTBP
$0.43
-$0.01-1.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.22M | 2.75M | 1.15M | 833.00K | 1.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.60M | 3.38M | 1.51M | 1.93M | 3.76M |
| Operating Income | -5.60M | -3.38M | -1.51M | -1.93M | -3.76M |
| Income Before Tax | -23.03M | -3.11M | -1.43M | -776.00K | -3.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.03M | -3.11M | -1.43M | -776.00K | -3.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.03M | -3.11M | -1.43M | -776.00K | -3.78M |
| EBIT | -5.60M | -3.38M | -1.51M | -1.93M | -3.76M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.23 | -0.83 | -0.55 | -0.33 | -1.67 |
| Normalized Basic EPS | -1.11 | -0.49 | -0.32 | -0.47 | -1.04 |
| EPS Diluted | -2.23 | -0.83 | -0.55 | -0.33 | -1.67 |
| Normalized Diluted EPS | -1.11 | -0.49 | -0.32 | -0.47 | -1.04 |
| Average Basic Shares Outstanding | 12.98M | 3.94M | 2.77M | 2.35M | 2.26M |
| Average Diluted Shares Outstanding | 12.98M | 3.94M | 2.77M | 2.35M | 2.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.63% | -2.73% | -- | -- | -- |